Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

作者：Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo · 发表于：The Lancet Oncology · 年份：2019 · DOI：10.1016/s1470-2045(19)30167-6 · 被引用次数：1707 · 研究领域：Cancer Immunotherapy and Biomarkers、HER2/EGFR in Cancer Research、Lung Cancer Treatments and Mutations